Lines of investigation
Antibiotic-induced intestinal dysbiosis. Modulation of the intestinal microbiota through prebiotics obtained from milk.
Metagenomic studies of changes in the composition and diversity of intestinal bacteria induced by antibiotics such as clindamycin, neomycin or bacitracin in mouse models. Evaluation of the biological properties of products obtained from milk, such as lactoferrin protein or whey and buttermilk by-products, as modulators of the microbiota and the intestinal immune system.
Gut microbiota, inmune system and intestinal motility
Role of the gut microbiota in the immune system activation and intestinal motor function regulation in the Functional Gastrointestinal and Motility Disorders (FGIMDs).
Effects of the gut microbiota on the regulation of the Toll-like receptors (TLR), which recognize pathogen associated microbial patterns (PAMPs), and how these receptors can modulate the intestinal motor function by interacting with the serotonergic system or other neurotransmitters like acetyl-choline, nitric oxide or hydrogen sulphide (H2S).
Organometallic compounds as anticancer drugs
Evaluation of gold and ruthenium complexes compounds as drugs against colon cancer. Study of Caco-2 cells viability in the presence of new innovative designed compounds. Studies of action mechanism of the selective compounds: oxidative stress, expression of genes involved in cancer, apoptosis, cell cycle, caspases. Confirmation of the anticancer effect of the compounds in primary cultures of mouse colon tumors.
Carbon nanotubes as a drug delivery system for intestinal diseases
Evaluation of single-walled carbon nanotubes as a novel drug delivery system for intestinal diseases like colon cancer. Studies of toxicity, oxidative stress and effects on intestinal motility in Caco-2 cells and rabbit models.